Scientific Reports (Jun 2024)

Association of blood group O with a recurrent risk for acute lower gastrointestinal bleeding from a multicenter cohort study

  • Sho Suzuki,
  • Naoyuki Tominaga,
  • Tomonori Aoki,
  • Eiji Sadashima,
  • Tadashi Miike,
  • Hiroshi Kawakami,
  • Katsumasa Kobayashi,
  • Atsushi Yamauchi,
  • Atsuo Yamada,
  • Jun Omori,
  • Takashi Ikeya,
  • Taiki Aoyama,
  • Yoshinori Sato,
  • Takaaki Kishino,
  • Naoki Ishii,
  • Tsunaki Sawada,
  • Masaki Murata,
  • Akinari Takao,
  • Kazuhiro Mizukami,
  • Ken Kinjo,
  • Shunji Fujimori,
  • Takahiro Uotani,
  • Minoru Fujita,
  • Hiroki Sato,
  • Toshiaki Narasaka,
  • Junnosuke Hayasaka,
  • Tomohiro Funabiki,
  • Yuzuru Kinjo,
  • Akira Mizuki,
  • Shu Kiyotoki,
  • Tatsuya Mikami,
  • Ryosuke Gushima,
  • Hiroyuki Fujii,
  • Yuta Fuyuno,
  • Takuto Hikichi,
  • Yosuke Toya,
  • Kazuyuki Narimatsu,
  • Noriaki Manabe,
  • Koji Nagaike,
  • Tetsu Kinjo,
  • Yorinobu Sumida,
  • Sadahiro Funakoshi,
  • Kiyonori Kobayashi,
  • Tamotsu Matsuhashi,
  • Yuga Komaki,
  • Mitsuru Kaise,
  • Naoyoshi Nagata

DOI
https://doi.org/10.1038/s41598-024-64476-9
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 9

Abstract

Read online

Abstract The relationship between blood group and rebleeding in acute lower gastrointestinal bleeding (ALGIB) remains unclear. This study aimed to investigate the association between blood group O and clinical outcomes in patients with ALGIB. The study included 2336 patients with ALGIB whose bleeding source was identified during initial endoscopy (from the CODE BLUE-J Study). The assessed outcomes encompassed rebleeding and other clinical parameters. The rebleeding rates within 30 days in patients with blood group O and those without blood group O were 17.9% and 14.9%, respectively. Similarly, the rates within 1 year were 21.9% for patients with blood group O and 18.2% for those without blood group O. In a multivariate analysis using age, sex, vital signs at presentation, blood test findings, comorbidities, antithrombotic medication, active bleeding, and type of endoscopic treatment as covariates, patients with blood group O exhibited significantly higher risks for rebleeding within 30 days (odds ratio [OR] 1.31; 95% confidence interval [CI] 1.04–1.65; P = 0.024) and 1 year (OR 1.29; 95% CI 1.04–1.61; P = 0.020) compared to those without blood group O. However, the thrombosis and mortality rates did not differ significantly between blood group O and non-O patients. In patients with ALGIB, blood group O has been identified as an independent risk factor for both short- and long-term rebleeding.